(Q36379372)

13 August 2017

1 reference

title

The small-molecule immune response modifier imiquimod--its mode of action and clinical use in the treatment of skin cancer (English)

1 reference

13 August 2017

Michael P Schön

1

0 references

author name string

Margarete Schön

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Expert Opinion on Therapeutic Targets

13 August 2017

published in

1 reference

13 August 2017

volume

10

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

69-76

1 reference

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Classical chemotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Management of malignant melanoma: new developments in immune and gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Apoptosis and melanoma: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Cleavage of PITSLRE kinases by ICE/CASP-1 and CPP32/CASP-3 during apoptosis induced by tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Regulation of Fas-mediated apoptosis by N-ras in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Induction of apoptosis by cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

21 January 2018

Squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Nonmelanotic skin cancer and solar keratoses. The quiet 20th century epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Xeroderma pigmentosum: biochemical and genetic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Apoptosis in the pathogenesis and treatment of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Protracted cutaneous disorders in association with low CD4+ lymphocyte counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Metastatic basal cell carcinoma in acquired immunodeficiency syndrome-related complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Multiple basal cell carcinomas associated with hairy cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Expression of interferon-gamma receptors and interferon-gamma-induced up-regulation of intercellular adhesion molecule-1 in basal cell carcinoma; decreased expression of IFN-gamma R and shedding of ICAM-1 as a means to escape immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Guidelines for the management of basal cell carcinoma. British Association of Dermatologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Interventions for basal cell carcinoma of the skin: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Imiquimod for the treatment of skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Role of imiquimod in skin cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Treatment of multiple basal cell carcinomas in the scalp with imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Topically applied imiquimod inhibits vascular tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Gene expression in actinic keratoses: pharmacological modulation by imiquimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

Sunburn and p53 in the onset of skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.1.69

21 January 2018

Identifiers

DOI

10.1517/14728222.10.1.69

1 reference

13 August 2017

1 reference